Business Context and Reporting Period
This Form 8-K Current Report was filed by AngioDynamics, Inc. on November 19, 2012. The filing reports significant changes in executive leadership, specifically the announced retirement of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and associated compensation arrangements rather than financial performance results.
Material Changes and Executive Transitions
- Departure of CFO: D. Joseph Gersuk, age 62, announced his retirement effective January 31, 2013.
- Appointment of New CFO: Mark T. Frost was hired effective November 30, 2012, to succeed Mr. Gersuk no later than January 31, 2013.
- Successor Background: Mr. Frost previously served as CFO of Albany Molecular Research Inc. and held finance roles at Smith & Nephew Endoscopy and General Electric.
Compensation, Agreements, and Risks
Retirement Arrangement (Mr. Gersuk)
- Continuation of base salary and benefits from February 1, 2013, through September 30, 2013.
- Payment of accrued vacation and a pro-rated portion of the fiscal year 2013 bonus.
- Equity awards will continue to vest through January 31, 2015.
Employment Arrangement (Mr. Frost)
- Base Salary: $345,000 per year.
- Target Bonus: 50% of base salary.
- Perquisites: $1,200 monthly car allowance and up to $1,500 reimbursement for legal fees.
- Severance (Termination without Cause): 12 months of base salary if terminated prior to the second anniversary of the start date (subject to CEO appointment conditions).
Change in Control Agreement (Mr. Frost)
- Trigger Events: Includes beneficial ownership of >40% of voting securities, majority board change, merger, or liquidation.
- Severance upon Change in Control: 1.5 times annual base salary plus unpaid/prorated bonus and unused vacation if terminated without Cause or for Good Reason.
- Definitions: "Cause" includes willful failure to perform, injurious conduct, or criminal conviction. "Good Reason" includes significant reduction in duties, title, or compensation.
Investor Verification Checklist
- Verify the exact transition date for Mr. Frost assuming the CFO role (stated as no later than January 31, 2013).
- Review the attached Exhibit 10.1 (Retirement Agreement) and Exhibit 10.2 (Change in Control Agreement) for full legal terms.
- Assess the impact of the 1.5x severance multiplier on potential future M&A transaction costs.
- Confirm the vesting schedule details for Mr. Gersuk's equity awards extending to 2015.